Oxford, January 21, 2009 - Oxford Gene Technology (OGT) is pleased to announce a settlement of the lawsuit it filed in the United States Federal Court for the District of Delaware against BioArray Solutions Ltd. of Warren, NJ in May 2008, for alleged infringement of OGT’s patent numbers US 6,307,039, US 6,770,751 and US 7,192,707. BioArray has consistently denied that it infringed.
As a result of the settlement, OGT entered into a licence agreement with BioArray, now part of Immucor, giving them worldwide rights in the field of molecular immunohaematology for OGT’s Family 6 patents. These describe the use of microarray technology to detect variations in DNA sequences e.g. SNPs or different lengths of tandem repeat regions.
Dr Michael Bennett, Vice President Licensing and Patents at OGT, said: “We are delighted that the legal situation with BioArray is now resolved. At OGT, we operate a flexible licensing programme and we’re pleased to be able to include BioArray in that programme.”
The licence will remain valid for the patents’ lifetime. Financial details were not disclosed.
About Oxford Gene Technology
Founded in 1995 by the pioneer of Southern Blotting and microarray technologies, Professor Sir Edwin Southern, OGT is based near Oxford, UK.
The key focus areas of OGT include:
1. High Throughput Microarray Services. With a processing capacity of over 1,000 samples per week, applications available include aCGH, CNV, methylation studies and miRNA.
2. Cytogenetics products and services for high resolution detection of chromosomal abnormalities. OGT offers a range of high resolution oligonucleotide arrays, labelling kits and analysis software that together provide a unique, comprehensive solution for cytogenetics.
3. Digital microarrays/ Single Cell analysis. OGT’s innovative, patent-protected technology development programme is aimed at analysing genomic events at the single cell level for major applications such as stem cell and cancer biology.
4. Licensing. OGT operates an open licensing policy which has successfully provided access for a number of companies to OGT’s fundamental intellectual property, particularly in the area of microarrays.
For further information on OGT products and services please visit http://www.ogt.co.uk/
